Harrisvaccines

Ames, United States Founded: 2005 • Age: 21 yrs Acquired By Merck Animal Health
Developer of vaccine technology for the treatment of infectious diseases

About Harrisvaccines

Harrisvaccines is a Healthcare company based in Ames (United States) founded in 2005, and was acquired by Merck Animal Health in November 2015. Developer of vaccine technology for the treatment of infectious diseases. It operates in the Healthcare and Agriculture sectors. Harrisvaccines has raised $5 million across 3 funding rounds from investors including Merck Animal Health, NIFA and United States Department of Agriculture. Harrisvaccines offers products and services including Vaccines, Medicines, and DNA TraceBack. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its legal entity is Merck & Co., Inc. Its competitors include Avidity Biosciences, Sutro Biopharma and Antheia; 3 of its 3 listed competitors have raised funding.

Company details

Harrisvaccines uses RNA Particle (RP) technology to develop herd-specific vaccines. The technology developed by the company to develop the vaccine does not need the virus, instead, it needs only the data to determine the subtype or strain of a specific virus. The gene sequence of the virus is considered for developing the vaccine. Using its technology the company developed a vaccine called iPED in 2013 to fight Porcine Epidemic Diarrhea virus in an epidemic across Canada and North America. The company had also developed a Swine Influenza Vaccine, which was licensed for use as an aid in the prevention of disease caused by Swine Influenza, H3N2.

Key Metrics

Products & Services of Harrisvaccines

Harrisvaccines offers a comprehensive portfolio of products and services, including Vaccines, Medicines, and DNA TraceBack.

Vaccines
Animal Health Products

Vaccines for preventing diseases in companion and livestock animals

Medicines
Therapeutic Solutions

Medicines to treat animal health conditions and improve welfare

DNA TraceBack
Technology Solutions

Technology for tracking and monitoring animal genetics and health

Funding Insights of Harrisvaccines

Harrisvaccines has successfully raised a total of $5M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $5M
  • Total Rounds 3
  • First Round $460,000

    (Sep 2011)

  • Investors Count 2

All 3 funding rounds of Harrisvaccines with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Oct 2013Grant––
Oct 2011$5MSeries A––
–
Sep 2011$460,000Grant––
Valuation history

3 investors in total: 3 institutional.

Investors in Harrisvaccines

Harrisvaccines has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Merck Animal Health, NIFA and United States Department of Agriculture.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
nifa.usda.gov
Vaccine technology is developed and supplied for livestock animals.
1921merck-animal-health.comMadison, United States
Leadership is provided on agriculture, food, and rural development matters.
usda.gov
Premium access

Investor details for Harrisvaccines

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of Harrisvaccines

4 dated milestones of Harrisvaccines across 10 years, from founding to its latest funding, stage changes and deals.

  1. Founded Harrisvaccines is founded.
  2. Funding First funding round of $460K.
  3. Funding Latest funding round, Grant,.
  4. Exit Acquired by Merck Animal Health.

Competitors of Harrisvaccines

Harrisvaccines has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Antheia.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
aviditybiosciences.com2012San Diego, United States$142.54M253
Antibody-siRNA complexes are developed for cancer treatment.
sutrobio.com2003United States$171.85M235
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
antheia.bio2013Palo Alto, United States$152.37M50
Yeast cells are genetically engineered to produce medicinal products.
Premium access

Detailed competitors of Harrisvaccines

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Life Sciences Platforms & Tools

3 companies that operate in the same segment as Harrisvaccines (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Medidata is recognized as a leading provider of SaaS solutions for clinical research.
1999New York, New York, United StatesUSD 41.5 M
AI-based solutions for health management are provided.
2015Dallas, Texas, United StatesUSD 2.8 B1,111
Real-world health data is provided for research and decisions.
2012Menlo Park, California, United StatesUSD 259.16 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Harrisvaccines

Harrisvaccines was founded in 2005 and raised its 1st funding round 6 years after it was founded.

Harrisvaccines is headquartered in Ames, United States. It is registered at Ames, Iowa, United States.

Harrisvaccines is a funded company, having raised a total of $5M across 3 funding rounds to date. The company's 1st funding round was a Grant of $460K, raised on Sep 2011.

Harrisvaccines uses RNA Particle (RP) technology to develop herd-specific vaccines. The technology developed by the company to develop the vaccine does not need the virus, instead, it needs only the data to determine the subtype or strain of a specific virus. The gene sequence of the virus is considered for developing the vaccine. Using its technology the company developed a vaccine called iPED in 2013 to fight Porcine Epidemic Diarrhea virus in an epidemic across Canada and North America. The company had also developed a Swine Influenza Vaccine, which was licensed for use as an aid in the prevention of disease caused by Swine Influenza, H3N2.

Harrisvaccines's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.

Harrisvaccines offers Vaccines, Medicines, and DNA TraceBack.

Harrisvaccines has 3 investors. Key investors include Merck Animal Health, NIFA, and United States Department of Agriculture.

Harrisvaccines operates through Merck & Co., Inc..

Yes. Harrisvaccines was acquired by Merck Animal Health in November 2015.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available